Resources

Video resources

A story of wonder

A testimonial from Ashley, a mother and caregiver, about her daughter Autumn and their journey from diagnosis to treatment with RETHYMIC and beyond.

How RETHYMIC is manufactured

A look at each stage of the engineering process of RETHYMIC.

Understanding the congenital athymia patient journey

An edited recording of a webinar featuring a caregiver and a healthcare provider discussing the treatment journey and their partnership. This webinar was originally available as part of the Enzyvant CONNECT support program, which is now known as RETHYMIC Connect™.

Resources for your practice

Understanding Congenital Athymia

A guide to congenital athymia, how it’s diagnosed, and supportive care.

Download

A Guide to RETHYMIC

An informative brochure with study results, details about the engineering process, and more.

Download

Patient Case Study

A case study following a hypothetical patient with congenital athymia through the RETHYMIC treatment journey.

Download

Resources for your patients’ caregivers

Understanding and Living With Congenital Athymia

A guide to congenital athymia, from diagnosis to creating a care plan, specifically for caregivers.

Download

A Caregiver’s Guide to RETHYMIC

A guide to help caregivers better understand what RETHYMIC is, how it may help their child with congenital athymia, and more.

Download

The Road to RETHYMIC

A guide to help caregivers navigate the different steps of the congenital athymia treatment journey, from diagnosis to receiving RETHYMIC and beyond.

Download

Patient organizations:

There are several organizations for patients with immune system diseases that provide valuable support and education.

Jeffrey Modell logo

Jeffrey Modell Foundation is a global patient organization devoted to early and precise diagnoses, meaningful treatments, and ultimately, cures for primary immunodeficiencies (PIs).

Global Genes logo

Global Genes is dedicated to eliminating the burdens and challenges of rare diseases for patients and families.

Immune Deficiency Foundation logo

The Immune Deficiency Foundation is dedicated to improving the diagnosis, treatment, and quality of life of people affected by PIs by fostering a community empowered by advocacy, education, and research.

NORD logo

The National Organization for Rare Disorders is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them.

Father with a baby
Not an actual patient.
rethymic connect logo
Support and resources are available for patients with congenital athymia and their caregivers
Enroll your patients
Indication and Important Safety Information
Important Safety Information

Infection Control and Immunoprophylaxis: Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6-12 months after treatment with RETHYMIC. Follow infection control measures until the development of thymic function is established as measured by flow cytometry. Closely monitor patients for signs of infection. If fever develops, assess the patient via lab results and treat as clinically indicated. Patients should be maintained on immunoglobulin replacement therapy (IgG) and Pneumocystis jirovecii pneumonia prophylaxis until specified criteria are met. IgG trough level should be checked 2 months after stopping IgG to determine whether the patient may remain off IgG.

Graft versus Host Disease (GVHD): RETHYMIC may cause or exacerbate pre-existing GVHD, for which patients should be closely monitored and treated. Risk factors include atypical complete DiGeorge anomaly phenotype, prior hematopoietic cell transplantation (HCT), and maternal engraftment. Patients with specified elevated baseline T cell proliferative response to PHA should receive immunosuppressants to decrease this risk. GVHD may manifest as fever, rash, lymphadenopathy, elevated bilirubin and liver enzymes, enteritis, and/or diarrhea.

Autoimmune Disorders: Autoimmune-related adverse events occurred in patients treated with RETHYMIC. These events included thrombocytopenia, neutropenia, proteinuria, hemolytic anemia, alopecia, hypothyroidism, autoimmune hepatitis, autoimmune arthritis, transverse myelitis, albinism, hyperthyroidism, and ovarian failure. Monitor complete blood counts with differential, liver enzymes, serum creatinine, urinalysis, and thyroid function.

Renal Impairment: Pre-existing renal impairment is a risk factor for death.

Cytomegalovirus Infection (CMV): In the clinical studies, 4 out of 4 patients with pre-existing CMV infection died.

Malignancy: Due to underlying immune deficiency, patients who receive RETHYMIC may be at risk of developing post-treatment lymphoproliferative disorder. Patients should be tested for Epstein-Barr virus and CMV prior to and 3 months after treatment or after any suspected exposure.

Transmission of Serious Infections and Transmissible Infectious Diseases: Transmission of infectious disease may occur because RETHYMIC is derived from human tissue, and product manufacturing includes porcine- and bovine-derived reagents.

Vaccine Administration: Immunizations should not be given in patients treated with RETHYMIC until immune-function criteria have been met. Live virus vaccines should not be given until patients have met the criteria for and received inactivated vaccines.

Anti-HLA Antibodies: All patients should be screened for anti-HLA antibodies prior to receiving RETHYMIC. Patients testing positive should receive RETHYMIC from a donor who does not express those HLA alleles.

HLA Typing: HLA matching is required in patients who have received a prior HCT or a solid organ transplant. Patients who have received a HCT are at increased risk of developing GVHD after RETHYMIC if the HCT donor does not fully match with RETHYMIC.

Deaths: Of the 105 patients in clinical studies, 29 patients died, including 23 deaths in the first year (<365 days) after implantation.

Adverse Reactions: The most common (>10%) adverse events included hypertension, cytokine release syndrome, rash, hypomagnesemia, renal impairment/failure, thrombocytopenia, and GVHD.

Indication

RETHYMIC® is indicated for immune reconstitution in pediatric patients with congenital athymia.

Limitations of Use: RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency (SCID).

sumitomo logo

Sumitomo Pharma is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. RETHYMIC ®, RETHYMIC Connect™, and its logos are trademarks of Sumitomo Pharma Switzerland GmbH. © 2024 Sumitomo Pharma Switzerland GmbH. All rights reserved. RET-US-0381-24    11/2024